Inspire Investing LLC Has $396,000 Holdings in Pacira BioSciences, Inc. $PCRX

Inspire Investing LLC grew its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 21.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,556 shares of the company’s stock after purchasing an additional 2,868 shares during the period. Inspire Investing LLC’s holdings in Pacira BioSciences were worth $396,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Doma Perpetual Capital Management LLC grew its stake in shares of Pacira BioSciences by 3.2% in the first quarter. Doma Perpetual Capital Management LLC now owns 1,804,069 shares of the company’s stock valued at $44,831,000 after buying an additional 56,220 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Pacira BioSciences in the first quarter valued at $32,506,000. Goldman Sachs Group Inc. grew its stake in shares of Pacira BioSciences by 49.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after buying an additional 367,869 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Pacira BioSciences by 88.3% in the first quarter. Jacobs Levy Equity Management Inc. now owns 855,488 shares of the company’s stock valued at $21,259,000 after buying an additional 401,227 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Pacira BioSciences by 392.2% in the first quarter. American Century Companies Inc. now owns 667,423 shares of the company’s stock valued at $16,585,000 after buying an additional 531,831 shares in the last quarter. 99.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Pacira BioSciences in a research note on Wednesday, October 8th. Truist Financial raised shares of Pacira BioSciences from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research report on Friday, July 25th. Finally, Zacks Research raised shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Pacira BioSciences currently has an average rating of “Hold” and a consensus target price of $33.40.

Insider Activity

In other news, Director Marcelo Bigal sold 4,912 shares of the business’s stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $23.67, for a total value of $116,267.04. Following the completion of the sale, the director owned 11,393 shares of the company’s stock, valued at approximately $269,672.31. The trade was a 30.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 6.40% of the company’s stock.

Pacira BioSciences Trading Down 0.4%

Shares of Pacira BioSciences stock opened at $22.26 on Tuesday. The firm has a 50-day moving average of $25.42 and a 200-day moving average of $24.82. The stock has a market cap of $1.00 billion, a PE ratio of -8.01 and a beta of 0.40. Pacira BioSciences, Inc. has a 52-week low of $15.92 and a 52-week high of $27.64. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.91 and a current ratio of 2.38.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Tuesday, August 5th. The company reported $0.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. The company had revenue of $181.10 million during the quarter, compared to analysts’ expectations of $183.11 million. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. Pacira BioSciences’s quarterly revenue was up 1.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.96 earnings per share. Pacira BioSciences has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Pacira BioSciences, Inc. will post 2.41 EPS for the current year.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.